KR20240135818A - 보체 인자의 저해제 및 이의 용도 - Google Patents

보체 인자의 저해제 및 이의 용도 Download PDF

Info

Publication number
KR20240135818A
KR20240135818A KR1020247027150A KR20247027150A KR20240135818A KR 20240135818 A KR20240135818 A KR 20240135818A KR 1020247027150 A KR1020247027150 A KR 1020247027150A KR 20247027150 A KR20247027150 A KR 20247027150A KR 20240135818 A KR20240135818 A KR 20240135818A
Authority
KR
South Korea
Prior art keywords
compound
mmol
pharmaceutically acceptable
disease
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027150A
Other languages
English (en)
Korean (ko)
Inventor
딘 알. 아르티스
콜린 피. 레슬리
루카 비. 마일레오
클라우디아 베토
페데리코 소라나
브루노 디 굴리엘모
치아라 파드로니
페데리카 파롤디
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20240135818A publication Critical patent/KR20240135818A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247027150A 2022-01-14 2023-01-13 보체 인자의 저해제 및 이의 용도 Pending KR20240135818A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299712P 2022-01-14 2022-01-14
US63/299,712 2022-01-14
PCT/US2023/010783 WO2023137166A1 (en) 2022-01-14 2023-01-13 Inhibitors of complement factors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240135818A true KR20240135818A (ko) 2024-09-12

Family

ID=87279676

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027150A Pending KR20240135818A (ko) 2022-01-14 2023-01-13 보체 인자의 저해제 및 이의 용도

Country Status (10)

Country Link
US (1) US12522619B2 (https=)
EP (1) EP4463462A4 (https=)
JP (1) JP2025502254A (https=)
KR (1) KR20240135818A (https=)
CN (1) CN118715231A (https=)
AU (1) AU2023207988A1 (https=)
CA (1) CA3248405A1 (https=)
IL (1) IL314164A (https=)
MX (1) MX2024008710A (https=)
WO (1) WO2023137166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1971664B1 (en) 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
KR20100031723A (ko) * 2007-07-07 2010-03-24 이데미쓰 고산 가부시키가이샤 크리센 유도체 및 이를 이용한 유기 전계 발광 소자
KR101233377B1 (ko) * 2008-12-30 2013-02-18 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
TWI532741B (zh) * 2013-09-04 2016-05-11 喜星素材股份有限公司 含吡唑之多環化合物及使用其之有機發光裝置
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101981245B1 (ko) * 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102496411B1 (ko) * 2016-01-06 2023-02-06 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10646488B2 (en) * 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2019240471A1 (ko) 2018-06-11 2019-12-19 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574917B (zh) 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) * 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) * 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
CN113045585A (zh) * 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用
CN113831332B (zh) * 2021-10-29 2024-06-18 长春海谱润斯科技股份有限公司 一种含氮杂环衍生物及其在有机电致发光器件中的应用

Also Published As

Publication number Publication date
IL314164A (en) 2024-09-01
US12522619B2 (en) 2026-01-13
AU2023207988A1 (en) 2024-07-11
CA3248405A1 (en) 2023-07-20
EP4463462A4 (en) 2025-06-25
EP4463462A1 (en) 2024-11-20
MX2024008710A (es) 2024-09-27
CN118715231A (zh) 2024-09-27
WO2023137166A1 (en) 2023-07-20
JP2025502254A (ja) 2025-01-24
US20230265109A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
EP3668513B1 (en) Pyruvate kinase activators for use in treating blood disorders
EP2885288B1 (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
JP2022514079A (ja) Ｉｌ－１７の小分子調節物質としてのアミノ酸アニリド
KR20260035207A (ko) Pcsk9 억제제 및 이의 이용 방법
US12509474B2 (en) Inhibitors of complement factors and uses thereof
EP4232431B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
US20230365592A1 (en) Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
KR20240135818A (ko) 보체 인자의 저해제 및 이의 용도
WO2021032857A1 (en) Compounds and use thereof for the treatment of infectious diseases and cancer
HK40101053A (en) Compounds and compositions for treating conditions associated with lpa receptor activity
HK40101053B (en) Compounds and compositions for treating conditions associated with lpa receptor activity
TWI921300B (zh) Pcsk9抑制劑及其使用方法
HK40116712A (zh) 补体因子抑制剂及其用途
CN105612166A (zh) 治疗用水溶性(o-羰基)氨基磷酸酯前药
EA053254B1 (ru) Соединения и способы, подходящие для стабилизации мутаций фенилаланингидроксилазы
EA042084B1 (ru) Активаторы пируваткиназы для применения в лечении нарушений со стороны крови
BR112020003262B1 (pt) Composto, composição farmacêutica e usos do referido composto e da referida composição no tratamento de distúrbios do sangue

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000